Trevarx Biomedical is pioneering a new oncology paradigm through its novel small molecule radiopharmaceutical platforms. With two complementary programs — [211At]PTT (a therapeutic alpha-emitter) and [18F]FTT (a PET imaging biomarker) — Trevarx is enabling tumor-specific treatment and precision diagnostics for PARP-expressing cancers. With over $20M in prior research investment and exclusive IP licenses, Trevarx is advancing first-in-human trials in ovarian cancer and a multicenter Phase 2 study in breast cancer.
Lead Program & Pipeline
-
[211At]PTT: Alpha-emitting small molecule therapeutic targeting PARP-1 in solid tumors
-
Preclinical phase; preparing for Phase 1 in ovarian cancer
-
Strong early efficacy shown in preclinical neuroblastoma models
-
-
[18F]FTT: Companion PET imaging biomarker for PARP-1 tumor expression
-
In Phase 2 multicenter breast cancer trial led by MD Anderson, Penn, and Wash U
-
Over 296 patients imaged with consistent results and no adverse events
-
-
Pipeline expansion targeting prostate, breast, and additional PARP-expressing cancers
Technology Differentiators
-
First-ever alpha-emitting therapy (using Astatine-211) designed for subcellular DNA targeting via PARP-1
-
Dual diagnostic-therapeutic approach enables tumor-specific treatment selection
-
Biomarker product enables real-time identification of PARP-1 expression, addressing a major limitation of current genomic assays
-
Extensive validation through academic collaboration and $19M+ in non-dilutive NIH and DOD grants
Stage & Investment
-
Stage:
-
[18F]FTT: Phase 2, planning for pre-NDA meeting
-
[211At]PTT: Preclinical, Phase 1 IND in preparation
-
-
Funding Raised: $1.15M pre-seed + $5M non-dilutive
-
IP:
-
[18F]FTT: Issued patents through 2035 (licensed from WUSTL)
-
[211At]PTT: Patents from Penn, pending therapeutic method coverage
-
-
Collaborators: MD Anderson, University of Pennsylvania, WUSTL, University of Washington
What's Next
-
Complete [18F]FTT Phase 2 trial and initiate pre-NDA discussions with FDA
-
Secure strategic licensing partner for [18F]FTT in North America and Europe
-
Finalize IND-enabling work for [211At]PTT and submit Phase 1 IND
-
Apply for $2M SBIR Phase II and raise Seed/Series A to fund PTT clinical trials
-
Expand scientific infrastructure and business development capacity for commercialization